SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Conivaptan-d_4

Item No. 26455

CAS Registry No.:	1129433-63-1
Formal Name:	N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl-d_4]-[1,1'-biphenyl]-2-carboxamide
MF:	$C_{32}H_{22}D_4N_4O_2$
FW:	502.6
Chemical Purity:	≥98% (Conivaptan)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_4); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Conivaptan-d_4 is intended for use as an internal standard for the quantification of conivaptan (Item No. 23728) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Conivaptan-d_4 is supplied as a solid. A stock solution may be made by dissolving the conivaptan-d_4 in the solvent of choice, which should be purged with an inert gas. Conivaptan-d_4 is soluble in DMSO.

Description

Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V_{1A} and V_2 (K_is = 0.48 and 3.04 nM for rat liver V_{1A} and kidney V_2, respectively).[1] It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (K_i = 44 nM) but has no effect on AVP binding to anterior pituitary V_{1B} receptors at concentrations up to 100 µM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs) *in vitro* and the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.[2]

References

1. Tahara, A., Tomura, Y., Wada, K.-I., *et al.* Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V_{1A} and V_2 receptor antagonist, *in vitro* and *in vivo*. *J. Pharmacol. Exp. Ther.* **282(1)**, 301-308 (1997).
2. Zeynalov, E., Jones, S.M., Seo, J.W., *et al.* Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. *PLoS One* **10(8)**, e0136121 (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM